source
- FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vaxStrain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
- Silence Therapeutics' Phase 2 trial shows strong results for divesiran in polycythemia vera, shares jump 30%Silence Therapeutics reported that its nucleic‑acid drug divesiran achieved a 69% placebo‑adjusted response rate in a Phase 2 study of polycythemia vera patients. Safety was reported as clean, with…